BCAL Diagnostics Limited (AU:BDX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BCAL Diagnostics Limited has announced a major step in advancing breast cancer detection by securing a commercial license agreement with Sydney Breast Clinic to deploy its innovative BREASTEST® technology. This marks the beginning of the commercialization phase for the company, with the Sydney Breast Clinic being the first in Australia to offer BCAL’s non-invasive blood test for breast cancer detection. The partnership builds on a six-year collaboration and aims to strengthen clinical validation evidence in preparation for a commercial soft launch later this year.
For further insights into AU:BDX stock, check out TipRanks’ Stock Analysis page.